de Almeida, Luciana Y.; Mariano, Flavia S.; Bastos, Debora C.; Cavassani, Karen A.; Raphelson, Janna; Mariano, Vania S.; Agostini, Michelle; Moreira, Fernanda S.; Coletta, Ricardo D.; Mattos-Graner, Renata O.; Graner, Edgard published the artcile< The antimetastatic activity of orlistat is accompanied by an antitumoral immune response in mouse melanoma>, Recommanded Product: (S)-(S)-1-((2S,3S)-3-Hexyl-4-oxooxetan-2-yl)tridecan-2-yl 2-formamido-4-methylpentanoate, the main research area is orlistat antimetastatic activity antitumoral immune response melanoma; Experimental melanoma; Fatty acid synthase; Immune response; Metastasis; Orlistat.
Our group has previously shown that pharmacol. inhibition of FASN with orlistat decreases proliferation, promotes apoptosis, and reduces the metastatic spread of B16-F10 cells in exptl. models of melanoma. While most of the orlistat antitumor properties seem to be closely related to direct effects on malignant cells, its impact on the host immune system is still unknown. The effects of orlistat on the phenotype and activation status of infiltrating leukocytes in primary tumors and metastatic lymph nodes were assessed using a model of spontaneous melanoma metastasis (B16-F10 cells/C57BL/6 mice). Cells from the primary tumors and lymph nodes were mech. dissociated and immune cells phenotyped by flow cytometry. The expression of IL-12p35, IL-12p40, and inducible nitric oxide synthase (iNOS) was analyzed by qRT-PCR and production of nitrite (NO2-) evaluated in serum samples with the Griess method. Orlistat-treated mice exhibited a 25% reduction in the number of mediastinal lymph node metastases (mean 3.96 ± 0.78, 95% CI 3.63-4.28) compared to the controls (mean 5.7 ± 1.72; 95% CI 5.01-6.43). Taken together, these findings suggest that orlistat supports an antitumor response against exptl. melanomas by increasing CD80/CD81-pos. and IL-12-pos. DC populations, granzyme b/NKG2D-pos. NK populations, and perforin/granzyme b-pos. CD8 T lymphocytes as well as reducing Tregs counts within exptl. melanomas.
Cancer Chemotherapy and Pharmacology published new progress about Antitumor agents. 96829-58-2 belongs to class amides-buliding-blocks, and the molecular formula is C29H53NO5, Recommanded Product: (S)-(S)-1-((2S,3S)-3-Hexyl-4-oxooxetan-2-yl)tridecan-2-yl 2-formamido-4-methylpentanoate.
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics